Skip to Content
Morningstar

Karyopharm Therapeutics Inc KPTI

Morningstar Rating
Unlock
Stock XNAS Rating as of
$1.28 −0.10 (7.25%)
View Full Chart
As of Delayed Price Closed
Unlock our analysis with Morningstar Investor
Start Free Trial

About Quantitative Ratings

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.

Price vs Fair Value

View History
KPTI is trading within a range we consider fairly valued.
Price
$1.38
Fair Value
$1.91
Uncertainty
Extreme
1-Star Price
$7.75
5-Star Price
$3.38
Economic Moat
Cjb
Capital Allocation
—
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if KPTI is a good fit for your portfolio.
Get 7 Days Free

News

View All

Trading Information

Previous Close Price
$1.38
Day Range
$1.22–1.42
52-Week Range
$0.62–4.30
Bid/Ask
$1.25 / $1.29
Market Cap
$147.29 Mil
Volume/Avg
1.3 Mil / 1.8 Mil

Key Statistics

Price/Earnings (Normalized)
—
Price/Sales
0.86
Dividend Yield (Trailing)
—
Dividend Yield (Forward)
—
Total Yield
—

Company Profile

Karyopharm Therapeutics Inc is a commercial-stage pharmaceutical company pioneering novel cancer therapies and dedicated to the discovery, development, and commercialization of drugs directed against nuclear export for the treatment of cancer and other diseases. XPOVIO (selinexor), is approved in the U.S. in multiple hematologic malignancy indications, including in combination with Velcade (bortezomib) and dexamethasone for the treatment of adult patients with multiple myeloma after at least one prior therapy, in combination with dexamethasone for the treatment of adult patients with heavily pretreated multiple myeloma and as a monotherapy for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma. The company derives its revenue from United States.
Sector
Healthcare
Industry
Biotechnology
Stock Style Box
Small Value
Total Number of Employees
325
Website
https://www.karyopharm.com

Comparables

Valuation

View More
Metric
KPTI
VRDN
ERAS
Price/Earnings (Normalized)
 ———
Price/Book Value
 —3.480.96
Price/Sales
 0.862,162.20—
Price/Cash Flow
 ———
Price/Earnings
No chart available

Financial Strength

Metric
KPTI
VRDN
ERAS
Quick Ratio
 3.1417.9311.94
Current Ratio
 3.3718.2612.26
Interest Coverage
 −5.45−137.76—
Quick Ratio
KPTI
VRDN
ERAS

Profitability

Metric
KPTI
VRDN
ERAS
Return on Assets (Normalized)
 −42.20%−42.76%−22.08%
Return on Equity (Normalized)
 —−82.42%−27.20%
Return on Invested Capital (Normalized)
 −111.18%−50.70%−27.50%
Return on Assets
KPTI
VRDN
ERAS
See how this stock stacks up to its competitors with Morningstar Investor
Start Free Trial

Biotechnology Industry Comparables

Screen in Investor
Ticker
Name
Morningstar Rating for Stocks
Capital Allocation
Economic Moat
Market Cap
NVO
Novo Nordisk A/S ADRQprywpmjkFbhh$553.3 Bil
VRTX
Vertex Pharmaceuticals IncHrqxrshnVmcwxl$101.7 Bil
REGN
Regeneron Pharmaceuticals IncSkhvmkwfQszdmc$98.1 Bil
MRNA
Moderna IncNktlhxvjQqc$39.7 Bil
ARGX
argenx SE ADRNnqqycstRww$21.7 Bil
BNTX
BioNTech SE ADRXwrhcvxxNvk$20.8 Bil
ALNY
Alnylam Pharmaceuticals IncLbyqsvffcSzpkm$18.3 Bil
BMRN
Biomarin Pharmaceutical IncNqgflxqjDfwnxq$17.1 Bil
RPRX
Royalty Pharma PLC Class AFhnxwdhhqLlbxml$12.5 Bil
INCY
Incyte CorpBkgpqjdKcmvx$11.8 Bil

Sponsor Center